New Prostate Cancer Drug Could Lower Recurrence Risk
Patients with high-risk prostate cancer may see reduced recurrence and metastasis rates with a new combined drug regimen.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Should medical treatment prioritize aggressive, early-stage intervention to prevent future cancer recurrence?
Adding the drug apalutamide to standard hormone therapy before and after surgery may significantly reduce the risk of prostate cancer recurrence or death. These findings from a large Phase 3 study offer a potential new treatment strategy for patients with high-risk, localized prostate cancer.
Why it matters
Prostate cancer recurrence is a major concern for patients, and these findings suggest that a combined pre- and post-surgical regimen could offer better long-term disease control than surgery alone. This data provides clinicians with evidence for a potential new approach to managing high-risk disease.
In a Phase 3 study of 408 patients, adding apalutamide to hormone therapy reduced the risk of recurrence or death by 62% compared to surgery alone over a median follow-up of 37.8 months. While these results are promising, ongoing follow-up is required to confirm the impact on overall survival.
The players
Johnson & Johnson
A global healthcare company that develops pharmaceutical treatments for oncology and other medical conditions.
The details
Apalutamide works as an androgen receptor inhibitor that blocks hormones from binding to their receptors, effectively starving prostate cancer cells of the signals they need to grow. In this regimen, patients received 240 mg of the drug daily for six cycles before undergoing a radical prostatectomy and for six cycles afterward. This approach aims to address high-risk disease by attacking the cancer both before and after its surgical removal.
Timeline
2026: PROTEUS substudy results were presented at the ESMO Congress.
Health Landscape
The PROTEUS substudy represents a key effort to refine perioperative care for high-risk prostate cancer beyond standard surgical intervention. This development aligns with a broader shift in oncology toward integrating targeted therapies into early-stage treatment plans to improve long-term outcomes.
If you have been diagnosed with high-risk, localized prostate cancer, it is worth discussing these findings with your urologist or oncologist to understand if such regimens are relevant to your care plan. Be aware that this therapy can be associated with side effects like hot flushes and urinary incontinence.
The takeaway
Early data indicates that integrating targeted hormone therapy into the surgical process for prostate cancer may improve event-free survival. Discussing potential trial-based or established adjuvant therapies with your oncology team remains the best way to manage individual risk factors for recurrence.
Further reading
For more information on current treatment strategies, visit our Cancer section.
More information
You can view the full trial details in the PROTEUS substudy clinical trial information.
Live Poll
Should medical treatment prioritize aggressive, early-stage intervention to prevent future cancer recurrence?
